20 articles
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
Leading cancer experts reveal breakthrough strategies combining radiation with immune treatments to boost cancer-fighting effectiveness.
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
Scientists develop safer way to deliver immune-boosting genes directly to tumors, enhancing radiation therapy effectiveness.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Researchers developed a new radiotracer that targets cancer cells more effectively when combined with mTOR inhibition therapy.
Phase I trial shows NT-I7 safely increases lymphocyte counts and expands cancer-fighting T cells in high-grade glioma patients.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Inhibiting the mitophagy kinase PINK1 amplifies mitochondrial ROS, activating a BAX-caspase-GSDME cascade that destroys neuroblastoma cells via pyroptosis.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Quantum computing breakthrough accelerates development of photodynamic therapy drugs for cancer treatment in major healthcare competition.
Phase 1 trial tests innovative immunotherapy for multiple myeloma and lymphoma patients who didn't respond to standard treatments.
New study reveals optimal timing strategy for combining radiation and immunotherapy treatments in advanced lung cancer patients.
Engineered green tea compound nanoparticles activate cellular powerhouses to suppress tumor growth and improve immune response against melanoma.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
